

Supplementary Material

Table S1. Patient sample and experimental conditions. R= responder. NR= non-responder.

Patient	Time Point*	Responder status	miRNA RT-PCR	miRNA array	mRNA array
1	0 [†] , 3	R	X	X	X
1	0 [†] , 12	NR	X	X	X
2	0, 3	R	X	-	X
2	0, 12	R	X	-	X
3	0, 3	NR	X	X	X
3	0, 12	R	X	X	X
4	0, 3	R	X	X	X
4	0, 12	R	X	-	X
5	0, 3	NR	X	X	X
5	0, 12	-	-	-	-
6	0, 3	R	X	X	X
6	0, 12	NR	X	X	X
7	0, 3	R	X	X	X
7	0, 12	R	X	X	X
8	0, 3	R	X	X	-
8	0, 12	R	X	X	-
9	0, 3	R	X	X	X
9	0, 12	R	X	X	X
10	0, 3	R	X	X	X
10	0, 12	NR	X	X	X
11	0, 3	R	X	X	X
11	0, 12	R	X	X	X
12	0, 3	R	X	-	X
12	0, 12	R	X	-	X
13	0, 3	R	X	-	X
13	0, 12	R	X	-	X
14	0, 3	NR	X	X	X
14	0, 12	NR	X	X	X
15	0, 3	R	X	-	X
15	0, 12	R	X	-	X
16	0, 3	R	X	X	X
16	0, 12	R	X	X	X
17	0, 3	R	X	-	X
17	0, 12	R	X	-	X
18	0, 3	R	X	X	X
18	0, 12	R	X	X	X
19	0, 3	R	X	X	X
19	0, 12	R	-	-	-
20	0, 3	R	X	X	-
20	0, 12	-	-	-	-
21	0, 3	R	X	X	-
21	0, 12	R	X	X	X
22	0, 3	R	X	X	X
22	0, 12	R	X	X	X

23	0, 3	R	X	-	X
23	0, 12	R	X	-	X
24	0, 3	R	X	X	X
24	0, 12	NR	X	X	X
25	0, 3	R	X	X	X
25	0, 12	R	X	X	X
26	0, 3	NR	X	X	X
26	0, 12	NR	X	X	X
27	0, 3	R	X	-	X
27	0, 12	-	-	-	-
28	0, 3	R	X	X	X
28	0, 12	R	X	X	X
29	0, 3	R	-	X	X
29	0, 12	R	X	X	X
30	0, 3	R	X	X	X
30	0, 12	R	X	X	X
31	0, 3	R	X	X	X
31	0, 12	R	-	-	X
32	0, 3	NR	X	-	X
32	0, 12	R	X	-	X
33	0, 3	NR	X	X	X
33	0, 12	NR	X	X	X
34	0, 3	NR	X	-	X
34	0, 12	NR	X	-	X
35	0, 3	NR	X	X	X
35	0, 12	NR	X	X	X
36	0, 3	R	X	-	X
36	0, 12	R	X	-	X
37	0, 3	R	X	X	X
37	0, 12	NR	X	X	X
38	0, 3	R	X	X	-
38	0, 12	-	-	-	-
39	0, 3	NR	-	-	-
39	0, 12	NR	X	X	X
40	0, 3	R	X	X	X
40	0, 12	NR	X	X	X
41	0, 3	R	X	X	X
41	0,12	R	X	-	-
42	0, 3	NR	X	X	X
42	0, 12	-	-	-	-
43	0, 3	NR	X	-	X
43	0, 12	-	-	-	-

*In months; 0 = Baseline study prior to randomization and institution of treatment protocol;
†0 time point is the baseline value for both 3 and 12 month studies; †X, = measurement available, -, = no measurement available.

Table S2. Baseline characteristics by cohort

Parameter	miRNA cohort* (n=43)	Entire cohort* (n=47)
Age, yrs	47 [36-55]	47 [47-54]
Duration HF, months	4 [2-12]	4 [2-16]
Male	32 (74%)	34 (72%)
Race		
European ancestry	28 (65%)	31 (66%)
African ancestry	6 (14%)	6 (14%)
Other	9 (21%)	9 (19%)
NYHA		
Class II	23 (53%)	26 (55%)
Class III	20 (47%)	21 (45%)
Atrial fibrillation	8 (19%)	10 (21%)
Hx of Htn	17 (40%)	18 (38%)
eGFR [†]	83 [67-92]	83 [70-94]
LVEF, %	23 [20-33]	25 [19-33]
RVEF, %	26 [19-32]	27 [20-33]
EDVI, mL/m ²	103 [77-122]	105 [77-137]
ESVI, mL/m ²	81 [53-92]	82 [53-102]
SV, mL	53 [37-69]	56 [39-71]
HR, bpm	86 [73-95]	86 [73-95]
QRS, ms	104 [98-130]	104 [98-127]
Norepinephrine, pg/mL	475 [299-584]	467 [256-584]
SBP, mm Hg	104 [98-118]	103 [96-116]
PA Mean, mm Hg	26 [17-31]	23 [15-30]
CI, L/m ²	2.1 [1.8-2.7]	2.3 [1.8-2.7]
ACE inhibitor or ARB [‡]	42 (98%)	46 (98%)
MRA [§]	29 (67%)	29 (62%)
Diuretic	36 (84%)	37 (79%)
CRT-P or -D	0	0
ICD	4 (9%)	4 (9%)

*Median (interquartile range); [†]in ml/min/1.73m²; [‡]ACE = angiotensin converting enzyme, ARB = angiotensin receptor blocker; [§]mineralocorticoid receptor blocker.